NI201900123A - Anticuerpos que se unen específicamente a pd-1 y métodos de uso - Google Patents

Anticuerpos que se unen específicamente a pd-1 y métodos de uso

Info

Publication number
NI201900123A
NI201900123A NI201900123A NI201900123A NI201900123A NI 201900123 A NI201900123 A NI 201900123A NI 201900123 A NI201900123 A NI 201900123A NI 201900123 A NI201900123 A NI 201900123A NI 201900123 A NI201900123 A NI 201900123A
Authority
NI
Nicaragua
Prior art keywords
antibodies
methods
specifically bind
fragments
antigen
Prior art date
Application number
NI201900123A
Other languages
English (en)
Inventor
Chen Qiang
Cole Suzanne
Duffy Karen
Gardner Debra
Guo Yanxia
Hamel Damon
Hitchcock Shannon
Lacombe Ann
Luo Jinquan
Malaviya Ravi
I Orlovsky Yevgeniya
Soroosh Pejman
Swiecki Melissa
Wilkinson Deepti
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of NI201900123A publication Critical patent/NI201900123A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Los anticuerpos que se unen específicamente a PD-1 o fragmentos de unión al antígeno de estos, los polinucleótidos que codifican los anticuerpos o fragmentos, y los métodos de fabricación y uso de los anteriores son útiles en el tratamiento de trastornos inflamatorios o inmunitarios.
NI201900123A 2017-06-05 2019-12-04 Anticuerpos que se unen específicamente a pd-1 y métodos de uso NI201900123A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515188P 2017-06-05 2017-06-05
US201862648114P 2018-03-26 2018-03-26
US201862673185P 2018-05-18 2018-05-18

Publications (1)

Publication Number Publication Date
NI201900123A true NI201900123A (es) 2020-12-01

Family

ID=64562613

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201900123A NI201900123A (es) 2017-06-05 2019-12-04 Anticuerpos que se unen específicamente a pd-1 y métodos de uso

Country Status (23)

Country Link
US (3) US10995149B2 (es)
EP (1) EP3634995A4 (es)
JP (1) JP7235733B2 (es)
KR (1) KR20200014414A (es)
CN (1) CN110997712B (es)
AU (1) AU2018282094A1 (es)
BR (1) BR112019025574A2 (es)
CA (1) CA3065516A1 (es)
CL (1) CL2019003520A1 (es)
CO (1) CO2019013935A2 (es)
CR (1) CR20190550A (es)
EC (1) ECSP19086810A (es)
IL (1) IL271009A (es)
MA (1) MA52459A (es)
MX (1) MX2019014577A (es)
NI (1) NI201900123A (es)
PE (1) PE20200294A1 (es)
PH (1) PH12019502755A1 (es)
TW (1) TWI806873B (es)
UA (1) UA128035C2 (es)
UY (1) UY37761A (es)
WO (1) WO2018226580A2 (es)
ZA (1) ZA202000051B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3065125A1 (en) * 2017-06-02 2018-12-06 Bayer Aktiengesellschaft Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
AR114127A1 (es) 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
US20220298211A1 (en) * 2019-06-04 2022-09-22 Qiang Chen PLANT-PRODUCED mABs AGAINST CHIKUNGUNYA VIRUS WITH ENHANCED EFFECTOR FUNCTION AND EFFICACY
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
JP6856183B1 (ja) * 2019-07-30 2021-04-07 小野薬品工業株式会社 二重特異性抗体
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
CN115956087A (zh) 2020-05-26 2023-04-11 勃林格殷格翰国际有限公司 抗-pd-1抗体
WO2022156773A1 (en) * 2021-01-21 2022-07-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd Protein complexes targeting il12 pathway
AU2022272835A1 (en) 2021-05-13 2023-11-02 Foundation For Biomedical Research And Innovation At Kobe Anti-human pd-1 agonist antibody and pharmaceutical composition comprising the antibody for treating or preventing inflammatory diseases
AU2022294106A1 (en) * 2021-06-18 2024-01-25 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
WO2023089377A2 (en) 2021-11-19 2023-05-25 Mirobio Limited Engineered pd-1 antibodies and uses thereof
WO2024010861A2 (en) * 2022-07-06 2024-01-11 Santa Ana Bio, Inc. Methods and compositions for treating autoimmune, allergic and inflammatory diseases
CN116854820B (zh) * 2023-06-26 2024-02-06 华中科技大学同济医学院附属协和医院 Pd-1非阻断性清除抗体及其用途

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
JP2010535032A (ja) 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CN101970730A (zh) 2007-12-19 2011-02-09 森托科尔奥索生物科技公司 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
WO2010029434A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
EP2347038A4 (en) 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
JP5920929B2 (ja) 2010-03-11 2016-05-18 ユセベ ファルマ ソシエテ アノニム Ｐｄ−１抗体
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2643351A1 (en) 2010-11-24 2013-10-02 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
LT2970980T (lt) 2013-03-15 2018-10-25 Janssen Biotech, Inc. Gamybos būdas kontroliuoti c galinio lizino, galaktozės ir sialo rūgšties kiekį rekombinantiniuose baltymuose
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
RS59480B1 (sr) 2013-12-12 2019-12-31 Shanghai hengrui pharmaceutical co ltd Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena
CA2932476A1 (en) 2013-12-12 2015-06-18 Stemcentrx, Inc. Novel anti-dpep3 antibodies and methods of use
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN106232626B (zh) * 2014-03-27 2022-05-03 鸟石生物公司 结合人大麻素1(cb1)受体的抗体
PT3177644T (pt) * 2014-08-05 2021-01-13 MabQuest SA Reagentes imunológicos que se ligam a pd-1
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US10239942B2 (en) 2014-12-22 2019-03-26 Pd-1 Acquisition Group, Llc Anti-PD-1 antibodies
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
KR20180034588A (ko) 2015-07-30 2018-04-04 마크로제닉스, 인크. Pd-1-결합 분자 및 그것의 사용 방법
CA2993276A1 (en) 2015-08-11 2017-02-16 Yong Zheng Novel anti-pd-1 antibodies
EA201890630A1 (ru) 2015-09-01 2018-10-31 Эйдженус Инк. Антитела против pd-1 и способы их применения
EA201890790A1 (ru) * 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
RU2656181C1 (ru) 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
HUE051700T2 (hu) 2016-09-14 2021-03-29 Abbvie Biotherapeutics Inc Anti-PD-1 antitestek
WO2018053405A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
US11225523B2 (en) 2017-06-01 2022-01-18 Compugen Ltd. Triple combination antibody therapies
EP3679070A1 (en) 2017-09-07 2020-07-15 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
AR114127A1 (es) 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos

Also Published As

Publication number Publication date
US10995149B2 (en) 2021-05-04
CN110997712B (zh) 2024-03-19
CO2019013935A2 (es) 2020-01-17
JP7235733B2 (ja) 2023-03-08
EP3634995A4 (en) 2021-06-09
EP3634995A2 (en) 2020-04-15
KR20200014414A (ko) 2020-02-10
ECSP19086810A (es) 2020-02-28
MA52459A (fr) 2021-03-10
CR20190550A (es) 2020-04-05
US20230340155A1 (en) 2023-10-26
TWI806873B (zh) 2023-07-01
WO2018226580A3 (en) 2019-01-31
PH12019502755A1 (en) 2020-06-08
CL2019003520A1 (es) 2020-05-08
WO2018226580A2 (en) 2018-12-13
PE20200294A1 (es) 2020-02-05
MX2019014577A (es) 2020-07-29
UY37761A (es) 2019-01-02
JP2020522278A (ja) 2020-07-30
ZA202000051B (en) 2021-07-28
TW201906863A (zh) 2019-02-16
US20180355061A1 (en) 2018-12-13
UA128035C2 (uk) 2024-03-20
BR112019025574A2 (pt) 2020-06-23
IL271009A (en) 2020-01-30
US11746161B2 (en) 2023-09-05
US20210102000A1 (en) 2021-04-08
AU2018282094A1 (en) 2019-12-12
CA3065516A1 (en) 2018-12-13
CN110997712A (zh) 2020-04-10

Similar Documents

Publication Publication Date Title
ECSP19086810A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
CO2018005614A2 (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
EA202091540A1 (ru) Антитела к lilrb2
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CY1124730T1 (el) Αντισωματα εναντι pd-1 και χρησεις αυτων
EA202092435A2 (ru) Моноклональные антитела против bcma
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
UY37779A (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CO2018003436A2 (es) Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
WO2016062722A8 (en) Combination
PE20170256A1 (es) Proteinas de union y sus metodos de uso
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
UY37030A (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
CL2021000258A1 (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
PE20190209A1 (es) Anticuerpos anti-factor bb del complemento y uso de estos
GT201800034A (es) Anticuerpos anti-cd154 y métodos de uso de estos
EA201891299A1 (ru) Терапевтические антитела к cd9
CY1124445T1 (el) Αντισωματα αντι-ccl17